GlassScriptPhysician profile
Katherine Grelle
NPI 1770779332
$9,290.98
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $1,919 · 2021: $2,003 · 2022: $1,517 · 2023: $1,710 · 2024: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,875.11 | 2019-2024 | |
| Novo Nordisk INC | $1,517.39 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $807.86 | 2019-2023 | Trulance, Xifaxan |
| Lilly USA, LLC | $641.58 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $551.76 | 2019-2024 | Trintellix |
| Allergan, INC. | $484.81 | 2019-2022 | |
| Amgen INC. | $371.76 | 2019-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $342.24 | 2021-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $303.88 | 2019-2021 | |
| Pfizer INC. | $282.55 | 2019-2024 | |
| Amarin Pharma, INC. | $259.16 | 2019-2021 | |
| Astellas Pharma US INC | $248.34 | 2019-2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $219.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.98 | 2019-2023 | Jardiance |
| Esperion Therapeutics, INC. | $204.23 | 2020-2024 | Nexletol |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Grelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.